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Abstract: Appropriateness of diagnostic testing can be conventionally described as prescription of the right 
test, using the right method, at the right time, to the right patient, with the right costs and for producing the 
right outcome. There is ongoing debate about the real burden of inappropriateness in laboratory diagnostics. The 
media coverage of this issue has also recently led to either over- or under-emphasizing the clinical, organizational 
and economic consequences. This is quite problematic, inasmuch as some reliable data are available in the current 
scientific literature, showing that inappropriateness of laboratory testing can be as high as 70%. This is especially 
evident for, though not limited to, cancer biomarkers testing, in which the practice of avoidable tests ordering is 
dramatically magnified. The reasons beyond inappropriateness are many and multifaceted, entailing wrong habits, 
resistance to changes, poor culture, insufficient education and healthcare inefficiencies. There are many unfavorable 
consequences attributable to avoidable testing, including unjustified incremental costs, derangement of laboratory 
efficiency and potential patient safety issues. The tentative solutions to this important problem necessitate 
that policymakers, local hospital administrators, laboratory professionals, clinicians, patients' associations and 
diagnostic companies join the efforts and embark in the same landmark effort for disseminating a better culture of 
appropriateness. 
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Introduction
It is now undeniable that laboratory tests play a central role 
throughout the clinical decision making and managed care. 
This is noticeably confirmed by recent data attesting that 
up to 70% of the clinical decisions are substantially based 
on results of diagnostic tests (1). Laboratory tests ordering 
is a multidimensional enterprise, primarily driven by tests 
availability, physicians’ education, skill, habits, liability and 
legal protection (i.e., defensive medicine) (2). 
Despite remaining an essential aspect contributing to 
high-value and high-quality medical outcomes, the common 
practice of laboratory tests ordering carries a number 
of drawbacks. In particular, there is still ongoing debate 
about the real definition of appropriateness. In English 
dictionaries, the term is conventionally used for defining 
“something that is right, suitable or that fits for a certain 
scope, and that is right according to specific requirements”. 
The translation of this concept into laboratory medicine 
practice encompasses that appropriateness may be defined 
according to the so-called “six R” paradigm, which entails 
“prescription of the Right test, using the Right method, at 
the Right time, to the Right patient, with the Right costs 
and for producing the Right outcome” (3,4). 
Improving appropriateness of laboratory diagnostics 
is a challenging issue. One of the major hurdles is still 
represented by the unclear perception that laboratory 
professionals, physicians, patients, policymakers, patients’ 
associations, media as well as representatives of diagnostic 
companies have about the real burden of inappropriateness. 
In particular, the widespread media coverage of this issue 
has frequently contributed to portray many different (and 
often unreal) scenarios, which have ultimately led to over- 
or under-emphasizing the clinical, organizational and 
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economic consequences of inappropriate use of laboratory 
resources. This is quite problematic, inasmuch as some 
reliable data are instead available in the current scientific 
literature, and will be briefly revised in the following 
paragraph.
“Sizing” the problem
In an interesting study, Miyakis et al. retrospectively revised 
data of 25 laboratory tests obtained from over 400 patients 
hospitalized from both the emergency and the outpatient 
departments during a 6-month period (5). As many as 68% 
of these tests were found to have provided meaningless 
contribution to clinical management of patients, so 
unmasking a consistent over-usage of diagnostics tests. 
Notably, the number of inappropriate tests ordered by 
junior trainees was 20% higher than that of the senior staff. 
One of the most brilliant findings of this study was that an 
educational intervention on the medical personnel based on 
test-ordering behaviour, costs and factors contributing to 
overuse, was found to be effective to reduce the burden of 
inappropriateness, cutting down the number of avoidable 
tests by approximately 20% (i.e., from 2.01 to 1.58 tests/
patient/day). A similar outcome was reported in an ensuing 
hospital-based investigation (6). Briefly, a request form 
encompassing a limited number of appropriate laboratory 
tests was implemented for use by the junior medical staff, 
and the number of inappropriate tests consistently decreased 
by approximately 20%, with no substantial impact on 
patient outcome. This was accompanied by a 17% decrease 
of the overall hospital expenditure for laboratory testing. 
More recently, Sarkar et al. comprehensively reviewed 
the data of 200 patients with hemostatic problems and 
discovered that inappropriate tests were ordered in as many 
as 78% patients, so causing over $200,000 avoidable costs 
for the local hospital (7). Approximately 34% of the overall 
inappropriateness could be attributed to over-utilization. 
A reliable estimate of inappropriate laboratory testing has 
recently been provided by a multi-database systematic 
review, using keywords such as “utilization” and “laboratory 
test (s)” (8). The pooled results of this meta-analysis showed 
that the mean rates of overuse and underuse of laboratory 
testing were as high as 21% and 45%, with overutilization 
of in vitro diagnostics approximating 44% during initial 
testing. Most worryingly, the trends of overutilization did 
not show a meaningful variation throughout a 15-year 
period (i.e., between 1997 and 2012), so confirming that 
appropriateness is still an unmet target in the second decade 
of the third millennium.
Despite the burden of inappropriateness may virtually 
embraces all areas of diagnostic testing, there are some 
specific settings where the figures are particularly concerning. 
A recent national scale study carried out in Italy revealed that 
the number of cancer biomarkers ordered was higher than 
1 per every 5 individuals, which does not obviously match 
with the prevalence of cancer in the country (9). A further 
comprehensive analysis of data allowed to estimate that the 
burden of inappropriateness for breast cancer biomarkers 
was seemingly modest (i.e., 3%). Nevertheless, that of 
ovary cancer biomarker was found to be considerably high 
(i.e., 48%), whereas that of pancreas, gallbladder and other 
and unspecified parts of biliary tract cancer biomarkers 
was higher than 1,000%. This is an unreasonable number, 
even difficult to be figured out. Overall, the estimated 
inappropriateness of cancer biomarkers ordering in Italy was 
reported to be very close to 90%. These figures are not really 
different from those earlier provided by other two studies, 
the former also based in Italy and reporting that only 5% of 
the requests for cancer biomarkers testing were found to be 
coherent with international guidelines and recommendations 
(10), the latter based in Greece and concluding that proper 
requests for cancer biomarkers did not even approximate 
10% (11). An indirect authentication that inappropriateness 
in cancer biomarkers testing is dramatically high comes from 
an interesting study, showing that establishing a culture of 
appropriateness based on interdepartmental collaboration 
and implementation of guidelines can be effective to decrease 
test ordering by 78% (12). Therapeutic drugs monitoring 
makes no exception to this rule, wherein inappropriateness 
of test ordering for monitoring theophylline and digoxin 
plasma values was found to be as high as 64.2% (13) and 
45% (14) of all requests, respectively. As regards infectious 
diseases testing, Genç and Aksu estimated that between 
37‒45% of all serological tests for hepatitis B virus (HBV) 
may be avoidable (15).
As specifically regards tests repetition, a population 
cohort study carried out in Canada reported that nearly 
15% of follow-up orders for six common analytes (i.e., 
cholesterol, hemoglobin A1c, thyroid-stimulating hormone, 
vitamin B12, vitamin D and ferritin) were found to be 
avoidable (16). The inclination to unnecessarily repeat 
testing has detrimental effects on healthcare sustainability, 
as attested by another Canadian study showing that the 
annual cost of redundant laboratory tests repetition may 
be as high as 35.9 million dollars in that country (17). 
Notably, the reasons beyond inappropriateness are not 
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
Annals of Translational Medicine, 2017 Page 3 of 4
© Annals of Translational Medicine. All rights reserved. Ann Transl Med 2017atm.amegroups.com
limited to wrong habits, resistance to changes, poor culture 
and insufficient education, since the practice of prescribing 
avoidable tests is often triggered or worsened by healthcare 
inefficiencies. A paradigmatic example is represented by 
redundant laboratory testing for patients transferred from 
the emergency department, which can be as high as 40%, so 
eroding considerable hospital resources and disrupting both 
laboratory and emergency department efficiency (18).
Real and perceived consequences of 
inappropriateness
The consequences of inappropriately using laboratory 
resources are many and multifaceted. The first and rather 
obvious effect is that spending money for performing 
avoidable tests consumes precious assets which, in a world 
with limited resources and still plagued by an unprecedented 
economic crisis, may have an impact on the actual efficiency, 
sustainability and equity of care (19). With limited budget 
availability, the clinical laboratories around the globe are 
now forced to make difficult decisions about the number 
and types of tests to be maintained or implemented. Rather 
understandably, wasting resources for inappropriate testing 
makes it rather challenging to convince policymakers and 
local hospital administrators to implement new tests in the 
constantly expanding scenario of precision (personalized) 
medicine (20). The approach to diagnosing and treating 
many human disorders such as cancer and cardiovascular 
disease is now increasingly based on a personalized 
approach, entailing complex and often expensive tests. 
Epigenetics is strongly emerging as a valuable perspective 
for several multifactorial and complex conditions (21), 
which however necessitates huge investments for dedicated 
instrumentation and reagents, along with availability of 
skilled personnel. The sustainability of this revolution in 
laboratory diagnostics also passes through optimizing the 
use of conventional diagnostic investigations.
Another important aspect is that the final cost of a given 
laboratory test not only includes the direct cost of the assay, 
but also downstream expenditure which can be triggered 
by test results (22). It is now undeniable that the larger 
the number of tests ordered, the greater the chance of 
generating both false positive or false negative results, which 
may then promote follow-up, often invasive and expensive 
investigations, which in turn can have a serious impact on 
patients safety. To put it simply, the results of an apparently 
low-cost and easy test may then generate incremental costs 
due to additional testing, but may also trigger unjustified 
clinical management in the presence of unreliable data.
A final consideration needs to be made. There is 
a common misconception about the use of the term 
inappropriateness. Despite it is commonly acknowledged 
that inappropriateness is a synonymous of “bad use” or 
“overuse” of laboratory tests, appropriate test ordering also 
encompasses the prescription of the right test to the right 
patient, so meaning that underutilization of laboratory 
resources may also contribute to inappropriateness. 
Conclusions
Squeezed between limited resources and increasing 
demand for high-quality of care, the target of increasing 
appropriateness of laboratory test ordering remains one of 
the major challenges for the future of laboratory medicine 
(Figure 1). This inherently necessitates that policymakers, 
local hospital administrators, laboratory professionals, 
clinicians, patients' associations and diagnostic companies 
should all be embarked in the same landmark effort 
for disseminating a better culture. Developing and 
implementing reliable and sustainable solutions cannot 
discount a synergic endeavor and a strict cooperation 
among all these partners. What everybody needs to clearly 
acknowledge, is that we are all in the same boat, and we 
all have to row in the same direction, with the awareness 
that improving appropriateness in laboratory diagnostics 
not only will be effective for managing costs, but will also 
contribute to generate major clinical benefits and greater 
safety for the patients, so ultimately increasing the real and 
Figure 1 Causes and consequences of inappropriate laboratory 
testing.
Wrong habits
Resistance to changes
Poor culture
Insufficient education
Healthcare inefficiencies
INAPPROPRIATENESS
Unjustified 
incremental costs
Derangement of 
laboratory efficiency
Patient safety 
issues
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
Lippi et al. Inappropriateness in laboratory medicine
© Annals of Translational Medicine. All rights reserved. Ann Transl Med 2017atm.amegroups.com
Page 4 of 4
perceived value of diagnostic testing.
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